PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Revenue decline while AXSM shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
29.66%
R&D growth while AXSM reduces spending. John Neff would investigate strategic advantage.
16.61%
G&A growth 50-75% of AXSM's 23.75%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Operating expenses growth above 1.5x AXSM's 8.30%. Michael Burry would check for inefficiency.
25.48%
Total costs growth above 1.5x AXSM's 8.30%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A growth less than half of AXSM's 8.05%. David Dodd would verify if efficiency is sustainable.
-28.10%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-46.25%
EBITDA margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-27.47%
Both companies show declining income. Martin Whitman would check industry conditions.
-45.52%
Operating margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-14.81%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-27.92%
Both companies show declining income. Martin Whitman would check industry conditions.
-46.04%
Pre-tax margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Both companies show declining income. Martin Whitman would check industry conditions.
-46.04%
Net margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-20.00%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-20.00%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
6.47%
Share count reduction below 50% of AXSM's 0.23%. Michael Burry would check for concerns.
6.47%
Diluted share reduction below 50% of AXSM's 0.23%. Michael Burry would check for concerns.